Appili Therapeutics (APLIF) Stock Price, News & Analysis

Company Overview

Appili Therapeutics, Inc., headquartered in Halifax, Nova Scotia, is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel anti-infective and immuno-oncology therapeutics. Established in 2008 as a spinout from Acadia Pharmaceuticals, Appili has built a diversified pipeline of small-molecule drug candidates aimed at addressing unmet medical needs in antibiotic-resistant infections and rare genetic diseases.

The company’s lead program, ATI-2123, is a reformulated piperacillin-tazobactam designed to treat serious hospital-acquired and ventilator-associated pneumonias caused by multidrug-resistant Gram-negative bacteria. ATI-2123 has advanced into Phase 2 clinical trials, where it has shown potential for enhanced tissue penetration and stability compared to current standard therapies. In parallel, Appili is advancing ATI-1701, a potentiator of aminoglycoside antibiotics for multidrug-resistant tuberculosis, and ATI-1501, an adjunctive therapy targeting Pseudomonas aeruginosa infections in cystic fibrosis patients.

Appili operates research and development facilities in Canada, with a strategic presence in Boston, Massachusetts, to support U.S. regulatory activities and collaborations. The company partners with academic centers and contract research organizations across North America and Europe to optimize its clinical and preclinical programs. Leadership is headed by President and CEO Steve Shalita, a veteran of the biotechnology industry, alongside Chief Scientific Officer Brock Novick, Ph.D., whose expertise in microbiology underpins Appili’s scientific direction.

Since its inception, Appili has secured funding through public offerings on the OTC Markets and strategic partnerships, enabling steady progression of its development pipeline. The company’s mission is to provide innovative therapies that combat emerging infectious diseases and improve global patient outcomes. By focusing on high-barrier-to-entry indications and leveraging proprietary formulation technology, Appili Therapeutics aims to establish itself as a leader in the anti-infective and immuno-oncology arenas.

Key Stats

• Today's Range: $0.0137 to $0.0137
• 50-Day Range: $0.01 to $0.02
• 52-Week Range: $0.01 to $0.03
• Volume: N/A
• Average Volume: 24,512 shs
• Market Capitalization: $1.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Appili Therapeutics Stock Analysis - MarketRank™

Appili Therapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Appili Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Appili Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Appili Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the float of Appili Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Appili Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Appili Therapeutics does not currently pay a dividend.

Dividend Growth

Appili Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.04% of the float of Appili Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Appili Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Appili Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Appili Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.84% of the stock of Appili Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

APLIF Stock Analysis - Frequently Asked Questions

How have APLIF shares performed this year?

Appili Therapeutics' stock was trading at $0.0280 at the start of the year. Since then, APLIF stock has decreased by 51.1% and is now trading at $0.0137.

How were Appili Therapeutics' earnings last quarter?

Appili Therapeutics Inc. (OTCMKTS:APLIF) announced its earnings results on Tuesday, August, 13th. The company reported ($0.01) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.01).

How do I buy shares of Appili Therapeutics?

Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2024
• Today: 7/12/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:APLIF
• CIK: N/A
• Web: www.appilitherapeutics.com
• Phone: 902-442-4655
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.89 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -134.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.14
• Quick Ratio: 0.14

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 23.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 121,270,000
• Free Float: 106,908,000
• Market Cap: $1.66 million
• Optionable: Not Optionable
• Beta: -0.58